As federal prosecutors build their fraud case against Theranos founder Elizabeth Holmes, the trial revisits the company's early days and ambitious promises of revolutionary blood-testing technology. Confronted in the courtroom with internal lab notes and evidence of concealed machine failures, the defense faces the government's mounting proof of intentional deception.

As Theranos struggles with severe technical failures and a mounting cash crisis, Elizabeth Holmes and Ramesh Balwani aggressively push early investors for critical capital while deflecting demands for financial audits. Years later, federal prosecutors spotlight these high-pressure funding rounds in court, confronting key witnesses with evidence of the company's hidden instability.

As federal prosecutors examine the ties between Theranos and high-ranking military officials, retired General James Mattis takes the stand to address his past involvement with the company. Flashbacks reveal Elizabeth Holmes's aggressive pursuit of Pentagon support, contrasting her ambitious promises to the armed forces with the realities inside the laboratory. The episode explores the weight of high-profile endorsements and the scrutiny that follows when corporate claims face federal trial.

As Theranos faces catastrophic analyzer failures in its laboratory, leadership presents prospective high-profile investors with a glowing clinical validation report bearing a prominent pharmaceutical logo. Years later, federal prosecutors scrutinize the legitimacy of the endorsement in open court, questioning the true origins of the document.

After discovering that proprietary blood-testing technology is failing quality-control standards, young lab workers Tyler Shultz and Erika Cheung covertly document the company's altered data. When Tyler's warnings are dismissed by executive leadership and his own grandfather, the whistleblowers find themselves targeted by corporate intimidation as they attempt to smuggle out proof of the deception.

Following a damaging public exposé, Theranos leadership scrambles to contain the fallout while federal inspectors arrive unannounced to audit the company's clinical laboratory. Faced with compounding device failures and intense pressure from corporate executives to withhold records, laboratory staff must confront the reality of their testing practices as regulators close in.

As Theranos dismantles its laboratory servers, Elizabeth Holmes and Ramesh Balwani face federal wire fraud charges in court, prompting a pivotal legal decision that permanently separates their trials. With prosecutors arguing that corporate demonstrations were elaborate deceptions, the defense counters by contending that a failed business venture is not a crime.

Federal prosecutors present damning testimony and financial evidence as they detail the inner workings and deceptions of Theranos. With the government resting its wire fraud case, Elizabeth Holmes must prepare her own defense in the courtroom.

Elizabeth Holmes takes the stand in her federal fraud trial, deflecting operational blame onto her former partner while maintaining her own good faith. Under intense cross-examination, prosecutors confront her with damning evidence of doctored corporate reports and secret lab modifications. With the testimony concluded, the jury is sent to deliberate on eleven felony counts that will determine her fate.

The high-profile legal battle surrounding Theranos reaches its ultimate conclusion in a federal courtroom. As the remnants of the failed biotech company are dismantled, its leadership faces the final consequences of their actions.